- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | Maze Therapeutics files to sell 9.23M shares of common stock for holders | 2 | Seeking Alpha | ||
| 17.10. | Maze Therapeutics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 06.10. | Maze Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.10. | Maze Therapeutics appoints Hervé Hoppenot as board chairman | 10 | Investing.com | ||
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.10. | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | 133 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
| 03.10. | Maze Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 03.10. | Maze Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und sieht deutliches Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 19.09. | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | 17 | Insider Monkey | ||
| 15.09. | Maze Therapeutics stock price target raised to $34 at Guggenheim on promising PKU data | 3 | Investing.com | ||
| 15.09. | Maze Therapeutics: Guggenheim erhöht Kursziel nach vielversprechenden PKU-Studiendaten deutlich auf 34 $ | 1 | Investing.com Deutsch | ||
| 14.09. | Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M | 4 | MedCity News | ||
| 12.09. | Doppeltes Potenzial treibt Aktie an: H.C. Wainwright hebt Kursziel für Maze Therapeutics deutlich an | 2 | Investing.com Deutsch | ||
| 12.09. | Maze Therapeutics stock jumps as H.C. Wainwright raises price target on dual potential | 1 | Investing.com | ||
| 11.09. | Maze Therapeutics stock price target raised to $37 at BTIG on strong data | 1 | Investing.com | ||
| 11.09. | Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday | 3 | Benzinga.com | ||
| 11.09. | Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results | 5 | Investor's Business Daily | ||
| 11.09. | Maze Therapeutics climbs after early-stage trial data for rare disease drug | 7 | Seeking Alpha | ||
| 11.09. | Maze Therapeutics rises on $150M equity offering | 3 | Seeking Alpha | ||
| 11.09. | Maze Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | 228 | GlobeNewswire (Europe) | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABIVAX | 77,60 | -0,26 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| CYTOKINETICS | 50,000 | +0,81 % | Cytokinetics, Incorporated: Cytokinetics to Announce Third Quarter Results on November 5, 2025 | ||
| CELCUITY | 61,00 | 0,00 % | Celcuity Inc.: Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer | Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ("gedatolisib... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,400 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| REZOLUTE | 7,700 | -0,65 % | Rezolute passt Managerverträge an und beendet Aktienverkaufsprogramm | ||
| TREVI THERAPEUTICS | 10,640 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| PEPGEN | 4,500 | 0,00 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,550 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ARCELLX | 84,07 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 6,590 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,250 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 57,76 | 0,00 % | Mizuho startet Coverage für Kymera Therapeutics mit "Outperform" | ||
| HARMONY BIOSCIENCES | 29,600 | 0,00 % | Harmony Biosciences Rises 10.6% On Strong Q3 WAKIX Results And Upgraded Guidance | ||
| NUVALENT | 90,89 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,510 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen |
MAZE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 29,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.